These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39116784)

  • 21. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin Attenuates Sorafenib-Induced Myocardial Inflammation and Toxicity.
    Liu CH; Ho YC; Lee WC; Huang CY; Lee YK; Hsieh CB; Huang NC; Wu CC; Nguyen NUN; Hsu CC; Chen CH; Chen YC; Huang WC; Lu YY; Fang CC; Chang YC; Chang CL; Tsai MK; Wen ZH; Li CZ; Li CC; Chuang PK; Yang SM; Chu TH; Huang SC
    Environ Toxicol; 2024 Nov; 39(11):4844-4858. PubMed ID: 38884142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway.
    Tian G; Yu Y; Deng H; Yang L; Shi X; Yu B
    Clin Exp Pharmacol Physiol; 2021 Jun; 48(6):837-845. PubMed ID: 33527532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model.
    Madonna R; Pieragostino D; Cufaro MC; Del Boccio P; Pucci A; Mattii L; Doria V; Cadeddu Dessalvi C; Zucchi R; Mercuro G; De Caterina R
    J Cell Mol Med; 2022 Mar; 26(5):1380-1391. PubMed ID: 35122387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theaflavin 3,3'-digallate reverses the downregulation of connexin 43 and autophagy induced by high glucose via AMPK activation in cardiomyocytes.
    Shen Z; Chen Q; Jin T; Wang M; Ying H; Lu J; Wang M; Zhang W; Qiu F; Jin C; Zhao Y; Fu G
    J Cell Physiol; 2019 Aug; 234(10):17999-18016. PubMed ID: 30847932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
    Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
    Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.
    Corallo D; Pastorino F; Pantile M; Mariotto E; Caicci F; Viola G; Ponzoni M; Tonini GP; Aveic S
    J Exp Clin Cancer Res; 2020 Sep; 39(1):195. PubMed ID: 32962733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
    Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
    Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Empagliflozin on Vascular and Skeletal Mineralization in Hyperlipidemic Mice.
    Kalanski S; Pradhan S; Hon A; Xia Y; Safvati N; Rivera JC; Lu M; Demer LL; Tintut Y
    Vascul Pharmacol; 2024 Jun; 155():107376. PubMed ID: 38692418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway.
    Zhou Y; Wu W
    Cell Physiol Biochem; 2017; 41(6):2503-2512. PubMed ID: 28472796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
    Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
    ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.